Putting Science to Work

In the News

  • Syngene Q3 profit jumps 31% to Rs 59 cr.

    Business Standard-21/01/2016. Syngene reported a 31% jump in third quarter profits to Rs 59 crore and 23% growth in revenues to Rs 281 crore on improved business from its global clients to help build new drug discovery.

  • India has 'natural potential to grow' in CRO space, says Syngene CEO

    Outsourcing Pharma-14/01/2016. An exclusive interview with Peter Bains- CEO ,Syngene International Ltd -

  • Syngene appoints Jonathan Hunt as CEO-designate.

    Business Today-05/01/2016. Syngene appoints Jonathan Hunt as CEO-designate. Mr Hunt to take charge post retirement of current CEO Peter Bains. Mr Bains will continue as a member of the Syngene Board.

  • India price advantage helped Boost Business

    NDTV- 22/11/2015. Peter Bains, director and CEO at Syngene International, told NDTV that it witnessed strong growth across its business verticals in the second quarter, which was supported by significant cost advantage in India.

  • Syngene Story

    ET-NOW - 03/10/2015. An exclusive interview with Kiran Mazumdar Shaw, Peter Bains and Manoj Nerurkar on Syngene's operations and journey so far at the sprawling Syngene campus.

  • Syngene eyes capacity and capability expansion post-IPO

    Outsourcing Pharma-21/10/2015. Syngene says it will invest in new capacity and capabilities, including a viral testing facility, as it reports strong results in its first quarter post-IPO.

  • Syngene Q2 net profit rises 31% to Rs 52 crore

    Economic Times- 20/10/2015 .Syngene International, research arm of Biocon, today posted 30.69 per cent rise in its net profit at Rs 52.29 crore for the second quarter ended September 30 .

  • Syngene share strength reflects India's contract research opportunity

    Times of India-15/09/2015 .Among the major India players, Syngene is the only pure CRO, and is estimated to have 40% of the market.

  • Syngene International Jumps 32% From Issue Price Within One Quarter

    CNBC TV18- 15/09/2015. "Syngene International is targeting a growth of USD 250 million by FY2018", says Peter Bains CEO of the company) .

  • CROs Are Making Headlines -India’s drug discovery service sector is heating up

    Contract Pharma-11/09/2015 .Syngene says it is intent on establishing new capabilities and augmenting existing services across the discovery & development continuum..

Discovery Chemistry Discovery Biology Safety Assessment Large Molecule Development Chemical Development Formulation Development Stability Studies Polymer Research Integrated Discovery & Development Clinical Development Services Bioinfomatics Antibody Drug Conjugates Oligonucleotide Synthesis Contact Us

This site is best viewed in Firefox (29+), Chrome (35+), or Microsoft Internet Explorer (9+)

Social Widget